[Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005106
German
Original Title:
Zanubrutinib (nicht vorbehandelte chronische lymphatische Leukämie) - Addendum zum Projekt A22-130 (Dossierbewertung)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-41.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-41_zanubrutinib_addendum-zum-projekt-a22-130_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Antineoplastic Agents
- Hematologic Agents
- Protein Kinase Inhibitors
Keywords
- Zanubrutinib
- Leukemia – Lymphocytic – Chronic – B-Cell
- Benefit Assessment
- NCT03336333
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.